HUTCHMED (China) (NASDAQ: HCM)
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-24 | ||||||
REV |
FY 2021 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.250 | ||||||
REV | 356.128M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of HUTCHMED (China) (NASDAQ: HCM) through any online brokerage.
Other companies in HUTCHMED (China)’s space includes: Sundial Growers (NASDAQ:SNDL), Reata Pharmaceuticals (NASDAQ:RETA), Supernus Pharmaceuticals (NASDAQ:SUPN), Roivant Sciences (NASDAQ:ROIV) and Axsome Therapeutics (NASDAQ:AXSM).
The latest price target for HUTCHMED (China) (NASDAQ: HCM) was reported by Goldman Sachs on Wednesday, September 22, 2021. The analyst firm set a price target for 46.00 expecting HCM to rise to within 12 months (a possible 242.01% upside). 2 analyst firms have reported ratings in the last year.
The stock price for HUTCHMED (China) (NASDAQ: HCM) is $13.45 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for HUTCHMED (China).
HUTCHMED (China)’s H1 earnings are confirmed for Wednesday, August 24, 2022.
There is no upcoming split for HUTCHMED (China).
HUTCHMED (China) is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.